Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Authors

Selina Luger

Published

November 5, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Blood

Topics

DOI

10.1182/blood-2024-201595

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Authors

Selina Luger

Published

November 5, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Blood

Topics

DOI

10.1182/blood-2024-201595

Paper

Paper

Paper

Paper

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Abstract

Supporters

Journal

Topics

DOI

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Abstract

Supporters

Journal

Topics

DOI